Eli Lilly

News

After Roche’s exit, Blueprint passes Gavreto on to Rigel

Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug

News

Pfizer’s Litfulo becomes first NHS drug for alopecia areata

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition t

News

Could Novo-Catalent deal face antitrust hurdles?

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities

News

Britain will be first to get new Mounjaro device, says Lilly

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment

News

Lilly trumpets early success with deafness gene therapy

Eli Lilly’s acquisition of gene therapy specialist Akouos seems to have paid off, after the lead candidate in the deal restored hearing in a child with congenital deafness

News

FDA finds no link between GLP-1 drugs and suicide

The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid

After Roche’s exit, Blueprint passes Gavreto on to Rigel

Pfizer’s Litfulo becomes first NHS drug for alopecia areata

Could Novo-Catalent deal face antitrust hurdles?

Britain will be first to get new Mounjaro device, says Lilly

Lilly trumpets early success with deafness gene therapy

FDA finds no link between GLP-1 drugs and suicide

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Eli Lilly

Editor's Picks